Market capitalization | $50.97m |
Enterprise Value | $-36.55m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.56 |
EV/Sales (TTM) EV/Sales | -3.71 |
P/S ratio (TTM) P/S ratio | 5.17 |
P/B ratio (TTM) P/B ratio | 0.58 |
Revenue growth (TTM) Revenue growth | 56.62% |
Revenue (TTM) Revenue | $9.85m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
2 Analysts have issued a Kronos Bio Inc forecast:
2 Analysts have issued a Kronos Bio Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 9.85 9.85 |
57%
57%
|
|
Gross Profit | 8.13 8.13 |
174%
174%
|
|
EBITDA | -62 -62 |
47%
47%
|
EBIT (Operating Income) EBIT | -63 -63 |
47%
47%
|
Net Profit | -86 -86 |
24%
24%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kronos Bio, Inc. is a clinical-stage biopharmaceutical, which engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic transcription factors, small cell, prostate cancer, and MYC-driven cancers. The company was founded by Angela Koehler and Joshua Kazam in 2017 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Deborah Knobelman |
Employees | 10 |
Founded | 2017 |
Website | www.kronosbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.